Log in

NASDAQ:BMRNBioMarin Pharmaceutical Stock Price, Forecast & News

$126.06
-0.75 (-0.59 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$124.99
Now: $126.06
$127.41
50-Day Range
$94.85
MA: $113.45
$128.73
52-Week Range
$62.88
Now: $126.06
$129.89
Volume812,900 shs
Average Volume1.63 million shs
Market Capitalization$22.80 billion
P/E Ratio206.66
Dividend YieldN/A
Beta1.09
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More
BioMarin Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.70 billion
Cash Flow$0.64 per share
Book Value$17.38 per share

Profitability

Net Income$-23,850,000.00

Miscellaneous

Employees3,001
Market Cap$22.80 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

How has BioMarin Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMRN shares have increased by 45.1% and is now trading at $126.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioMarin Pharmaceutical.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for BioMarin Pharmaceutical.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported $0.44 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.32. The biotechnology company earned $502.07 million during the quarter, compared to analyst estimates of $468.77 million. BioMarin Pharmaceutical had a return on equity of 3.62% and a net margin of 6.31%. BioMarin Pharmaceutical's revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.32) EPS. View BioMarin Pharmaceutical's earnings history.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85-1.95 billion, compared to the consensus revenue estimate of $1.97 billion.

What price target have analysts set for BMRN?

21 brokerages have issued 1 year target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $150.00. On average, they expect BioMarin Pharmaceutical's share price to reach $119.70 in the next year. This suggests that the stock has a possible downside of 5.0%. View analysts' price targets for BioMarin Pharmaceutical.

Has BioMarin Pharmaceutical been receiving favorable news coverage?

Media coverage about BMRN stock has trended negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a news impact score of -2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about BioMarin Pharmaceutical.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.54%), Envestnet Asset Management Inc. (0.08%), DNB Asset Management AS (0.06%), State of Alaska Department of Revenue (0.05%), Gradient Investments LLC (0.03%) and Arden Trust Co (0.00%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi, V Bryan Lawlis and Willard H Dere. View institutional ownership trends for BioMarin Pharmaceutical.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, and Arden Trust Co. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, V Bryan Lawlis, and Willard H Dere. View insider buying and selling activity for BioMarin Pharmaceutical.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, Envestnet Asset Management Inc., Sanders Morris Harris LLC, Gradient Investments LLC, Fulton Bank N. A., and Patriot Financial Group Insurance Agency LLC. View insider buying and selling activity for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $126.06.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $22.80 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.